Squaric Ester-Based, pH-Degradable Nanogels: Modular Nanocarriers for Safe, Systemic Administration of Toll-like Receptor 7/8 Agonistic Immune Modulators.
Adjuvants, Immunologic
/ chemistry
Animals
Drug Carriers
/ chemistry
Drug Liberation
Esters
/ chemistry
Humans
Hydrogen-Ion Concentration
Immunotherapy
Mice, Inbred BALB C
Micelles
Nanogels
/ chemistry
Optical Imaging
Polymerization
Polymers
/ chemistry
Toll-Like Receptor 7
/ agonists
Toll-Like Receptor 8
/ agonists
Journal
Journal of the American Chemical Society
ISSN: 1520-5126
Titre abrégé: J Am Chem Soc
Pays: United States
ID NLM: 7503056
Informations de publication
Date de publication:
07 07 2021
07 07 2021
Historique:
pubmed:
25
6
2021
medline:
5
3
2022
entrez:
24
6
2021
Statut:
ppublish
Résumé
Small-molecular Toll-like receptor 7/8 (TLR7/8) agonists hold promise as immune modulators for a variety of immune therapeutic purposes including cancer therapy or vaccination. However, due to their rapid systemic distribution causing difficult-to-control inflammatory off-target effects, their application is still problematic, in particular systemically. To address this problem, we designed and robustly fabricated pH-responsive nanogels serving as versatile immunodrug nanocarriers for safe delivery of TLR7/8-stimulating imidazoquinolines after intravenous administration. To this aim, a primary amine-reactive methacrylamide monomer bearing a pendant squaric ester amide is introduced, which is polymerized under controlled RAFT polymerization conditions. Corresponding PEG-derived squaric ester amide block copolymers self-assemble into precursor micelles in polar protic solvents. Their cores are amine-reactive and can sequentially be transformed by acid-sensitive cross-linkers, dyes, and imidazoquinolines. Remaining squaric ester amides are hydrophilized affording fully hydrophilic nanogels with profound stability in human plasma but stimuli-responsive degradation upon exposure to endolysosomal pH conditions. The immunomodulatory behavior of the imidazoquinolines alone or conjugated to the nanogels was demonstrated by macrophages
Identifiants
pubmed: 34166595
doi: 10.1021/jacs.1c03772
pmc: PMC8267846
doi:
Substances chimiques
Adjuvants, Immunologic
0
Drug Carriers
0
Esters
0
Micelles
0
Nanogels
0
Polymers
0
Toll-Like Receptor 7
0
Toll-Like Receptor 8
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9872-9883Références
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Chem Soc Rev. 2014;43(20):6982-7012
pubmed: 24948004
Biomacromolecules. 2020 Jun 8;21(6):2246-2257
pubmed: 32255626
Exp Mol Pathol. 2009 Jun;86(3):215-23
pubmed: 19186176
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
J Immunol. 2009 Sep 1;183(5):3229-36
pubmed: 19667093
ACS Nano. 2012 Mar 27;6(3):2198-214
pubmed: 22381078
J Control Release. 2018 Nov 10;289:125-145
pubmed: 30223044
Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8098-103
pubmed: 27382168
ACS Appl Mater Interfaces. 2021 Feb 10;13(5):6011-6022
pubmed: 33507728
Macromol Rapid Commun. 2014 Sep;35(17):1522-7
pubmed: 24979656
Oncogene. 2008 Jan 7;27(2):190-9
pubmed: 18176600
Nano Today. 2015 Feb 1;10(1):93-117
pubmed: 25893004
Science. 2013 Sep 20;341(6152):1359-65
pubmed: 23929949
Int J Pharm. 2013 Sep 15;454(1):496-511
pubmed: 23415662
Bioconjug Chem. 2018 Aug 15;29(8):2741-2754
pubmed: 29969553
Expert Opin Biol Ther. 2004 Jul;4(7):1129-38
pubmed: 15268679
Nat Biotechnol. 2020 Mar;38(3):320-332
pubmed: 31932728
Adv Mater. 2018 Nov;30(45):e1803397
pubmed: 30276880
Nat Immunol. 2015 Apr;16(4):343-53
pubmed: 25789684
J Am Chem Soc. 2018 Oct 31;140(43):14300-14307
pubmed: 30277761
Sci Rep. 2017 Apr 21;7:46426
pubmed: 28429728
Nat Rev Immunol. 2013 Jun;13(6):453-60
pubmed: 23681101
Biomacromolecules. 2019 Feb 11;20(2):854-870
pubmed: 30608149
J Clin Pharmacol. 2007 Aug;47(8):962-9
pubmed: 17660481
J Med Chem. 2010 Jun 10;53(11):4450-65
pubmed: 20481492
Adv Drug Deliv Rev. 2017 May 15;114:79-101
pubmed: 28545888
Blood. 2005 Oct 1;106(7):2424-32
pubmed: 15976181
Cancer Res. 2021 Jan 1;81(1):27-34
pubmed: 32998999
Nat Immunol. 2021 Jan;22(1):41-52
pubmed: 33139915
ACS Chem Biol. 2014 May 16;9(5):1075-85
pubmed: 24690004
J Control Release. 2017 Feb 28;248:10-23
pubmed: 27940184
Immunity. 2013 Nov 14;39(5):806-18
pubmed: 24238338
J Med Chem. 2017 Mar 9;60(5):2084-2098
pubmed: 28146629
Angew Chem Int Ed Engl. 2018 Aug 13;57(33):10760-10764
pubmed: 30043442
Bioconjug Chem. 2016 Sep 21;27(9):2007-13
pubmed: 27504746
Chem Soc Rev. 2013 Nov 7;42(21):8220-36
pubmed: 23873344
Angew Chem Int Ed Engl. 2019 Oct 21;58(43):15390-15395
pubmed: 31397948
Cancer Immunol Immunother. 2013 Apr;62(4):787-99
pubmed: 23266830
Biomaterials. 2018 Sep;178:643-651
pubmed: 29573820
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Mar-Apr;8(2):271-99
pubmed: 26314803